


PATENT



I hereby certify that on November 3, 2005, which is the date I am signing this certificate, I am depositing this correspondence and all identified attachments with the U.S. Postal Service, postage prepaid, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Harry Lee

Applicant: **LEE, Sun**
Serial No.: **10/520,388**
Filed: **January 3, 2005**
Confirmation No.: **2704**
Title: **METHOD FOR PREPARING FUSION POLYPEPTIDE COMPRISING EPIDERMAL GROWTH FACTOR AND HUMAN SERUM ALBUMIN IN PLANTS**
Examiner: **N/A**
Art Unit: **N/A**
Attorney Docket No.: **20050-00004**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed below and on the attached form PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. § 1.97(g)), as an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists. The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. Copies of the cited documents are enclosed.

English Language Documents:

URDEA et al., "Chemical synthesis of a gene for human epidermal growth factor urogastrone and its expression in yeast," Proc. Natl. Acad. Sci. USA, 1983; 80:7461-7465

YAMAGATA et al., "Use of Bacillus brevis for efficient synthesis and secretion of human epidermal growth factor," Proc. Natl. Acad. Sci. USA, 1989; 86:3589-3593

SMITH and HUGGINS, "Successful Treatment of Experimental Escherichia coli Infections in Mice Using Phage: its General Superiority over Antibiotics," General Microbiology, 1982; 128:307-318

SAVAGE and HARPER, "Human Epidermal Growth Factor/Urogastrone: Rapid Purification Procedure and Partial Characterization," Biochemistry, 1981; 111:195-202
CAMBLE et al., U.S. Patent No. 3,917,824, Nov. 4, 1975
UMBECK, U.S. Patent No. 5,004,863, Apr. 2, 1991
FISCHHOFF et al., U.S. Patent No. 5,349,124, Sep. 20, 1994
HINCHEE et al., U.S. Patent No. 5,416,001, May 16, 1995
CARENZI et al., U.S. Patent No. 5,200,396, Apr. 6, 1993
WO 03/057889 A1 (Nexen Biotechnologies Inc.) 17 July 2003
WO 03/057890 A1 (Nexen Biotechnologies Inc.) 17 July 2003
WO 03/057891 A1 (Nexen Biotechnologies Inc.) 17 July 2003

Foreign Language Documents:


KR 9606121 (Daewoong Pharm Co. Ltd.) 09 May 1995 with English abstract
--

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached forms PTO/SB/08A and PTO/SB/08B (substitutes for form 1449/PTO) with initials or other appropriate marks, and that the references be made of record as cited references in the application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Therefore, no fee is required.

The Commissioner is authorized to charge JHK Law's Deposit Account No. **502486** for any fees required under 37 CFR §§ 1.16 and 1.17 and to credit any overpayment to said Deposit Account No. **502486**.

Respectfully submitted,

 *Kim, Reg. No. 56,814*

November 3, 2005

Date

Joseph Hyosuk Kim, Ph.D.
Reg. No. 41,425
Attorney for Applicants

JHK Law
P.O. Box 1078
La Canada, CA 91012-1078
Telephone: (818) 249-8177
Facsimile: (818) 249-8277

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1
-------	---	----	---

Complete if Known

Application Number	10/520,388
Filing Date	January 3, 2005
First Named Inventor	LEE, Sun
Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	20050-00004

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	B1	WO 03/057889 A1	07-17-2003	Nexen Biotechnologies Inc.	whole document	
	B2	WO 03/057890 A1	07-17-2003	Nexen Biotechnologies Inc.	whole document	
	B3	WO 03/057891 A1	07-17-2003	Nexen Biotechnologies Inc.	whole document	
	B4	KR 9606121	05-09-1995	Daewoong Pharm Co. Ltd.	Abstract	✓

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known**Application Number** 10/520,388**Filing Date** January 3, 2005**First Named Inventor** LEE, Sun**Art Unit** N/A**Examiner Name** N/A**Attorney Docket Number** 20050-00004

Sheet 1

of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	URDEA et al., "Chemical synthesis of a gene for human epidermal growth factor urogastrone and its expression in yeast," Proc. Natl. Acad. Sci. USA, 1983; 80:7461-7465	
	C2	YAMAGATA et al., "Use of Bacillus brevis for efficient synthesis and secretion of human epidermal growth factor," Proc. Natl. Acad. Sci. USA, 1989; 86:3589-3593	
	C3	SMITH and HUGGINS, "Successful Treatment of Experimental Escherichia coli Infections in Mice Using Phage: its General Superiority over Antibiotics," General Microbiology, 1982; 128:307-318	
	C4	SAVAGE and HARPER, "Human Epidermal Growth Factor/Urogastrone: Rapid Purification Procedure and Partial Characterization," Biochemistry, 1981; 111:195-202	

**Examiner
Signature****Date
Considered**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.